For example, Kübler et al. (15) reported a CV9103 prostate cancer vaccine containing self-adjuvanted mRNA (RNActive) with activation of TLR7, which induced broader immune responses and thereby prolonged the survival of patients with castration-resistant prostate cancer. This evidence concerns the gene TLR7 and prostate carcinoma.